This site is intended for US eye care professionals only.

SYFOVRE has 4 years of long-term safety data1,2

Through 2 years of OAKS and DERBY,

SYFOVRE has a demonstrated safety profile in a broad range of patients1

OAKS and DERBY Icon

ADVERSE REACTIONS IN STUDY EYE REPORTED IN ≥2% OF PATIENTS TREATED WITH SYFOVRE THROUGH YEAR 2 IN A COMBINED ANALYSIS1

 

SYFOVRE
MONTHLY
(n=419)

SYFOVRE
EOM
(n=420)

SHAM
POOLED
(n=417)

Ocular discomfort*

13%

10%

11%

Neovascular age-related macular degeneration* >

12%

7%

3%

Vitreous floaters

10%

7%

1%

Conjunctival hemorrhage

8%

8%

4%

Vitreous detachment

4%

6%

3%

Retinal hemorrhage

4%

5%

3%

Punctate keratitis*

5%

3%

<1%

Posterior capsule opacification

4%

4%

3%

Intraocular inflammation* >

4%

2%

<1%

Intraocular pressure increased

2%

3%

<1%

Additional Selected Safety Events

Optic ischemic neuropathy

1.7%

0.2%

0.0%

Deaths

6.7%

3.6%

3.8%

Endophthalmitis, retinal detachment, hyphema, and retinal tears were reported in <1% of patients.

  • No events of occlusive or nonocclusive retinitis or vasculitis in clinical trial2
    • Events of retinal vasculitis and/or retinal vascular occlusion have been reported in the real-world setting at an estimated rate of 1/10,000 (0.01%) per injection2†
    • Retinal vasculitis appears to be a first injection phenomenon at an estimated rate of 1/4,000; of first injections, the estimated rate of retinal vasculitis resulting in severe vision loss is 1/8,0002†
    • Discontinue treatment with SYFOVRE in patients who develop these events1

*The following reported items were combined1:

  • Ocular discomfort included: eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye
  • Neovascular age-related macular degeneration included: exudative age-related macular degeneration, choroidal neovascularization
  • Punctate keratitis included: punctate keratitis, keratitis
  • Intraocular inflammation included: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, anterior chamber flare

†Data on file from clinical trial and estimated real-world injections as of March 31, 2025. Injections are calculated based on vials distributed to eyecare professional practices and estimates of patient numbers (extrapolated from licensed data and inventory levels from key accounts, representative of our market).2

Safety profile in Years 0-2 of GALE2

Scroll to see full chart →Scroll to see more

OAKS and DERBY Icon

ADVERSE REACTIONS IN STUDY EYE REPORTED IN ≥2% OF PATIENTS TREATED WITH SYFOVRE2*

 

CONTINUED TREATMENT

SYFOVRE
MONTHLY
(n=250)

SYFOVRE
EOM
(n=268)

PREVIOUSLY UNTREATED

SYFOVRE
MONTHLY
(n=129)

SYFOVRE
EOM
(n=143)

nAMD*

13.9%

5%

8%

7%

Intraocular pressure increased

9%

8%

9%

3%

Cataract

7%

3%

5%

5%

Vitreous floaters

6%

3%

11%

7%

Ocular discomfort*

6%

4%

7%

7%

Conjunctival hemorrhage

5%

3%

10%

6%

Retinal hemorrhage

5%

3%

5%

2%

Additional AEs of interest in study eye, patient (%) events

Intraocular inflammation

12 (4.8%)

3 (1.1%)

6 (4.7%)

2 (1.4%)

Infectious endophthalmitis

3 (1.2%)

1 (0.4%)

1 (0.8%)

0

Ischemic optic neuropathy

1 (0.4%)

0

0

1 (0.7%)

Learn about AEs of interest in GALE >

  • Years 0-4 rates (OAKS, DERBY, and GALE)2:
    • Infectious endophthalmitis: (0.04% per injection)
    • ION: (0.04% per injection)
    • IOI†: (0.23% per injection)
  • No study events of occlusive or nonocclusive retinitis or vasculitis were reported in clinical trials2
    • Events of retinal vasculitis and/or retinal vascular occlusion have been reported in the real-world setting at an estimated rate of 1/10,000 (0.01%) per injection2‡
    • Retinal vasculitis appears to be a first injection phenomenon at an estimated rate of 1/4,000; of first injections, the estimated rate of retinal vasculitis resulting in severe vision loss is 1/8,0002‡
    • Discontinue treatment with SYFOVRE in patients who develop these events1

*The following reported items were combined2:

  • Ocular discomfort included: eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye
  • Neovascular age-related macular degeneration included: exudative age-related macular degeneration, choroidal neovascularization
  • Intraocular inflammation included: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, anterior chamber flare

†Excludes 4 lOl cases previously attributed to drug impurity in 2018.2

‡Data on file from clinical trial and estimated real-world injections as of March 31, 2025. Injections are calculated based on vials distributed to eyecare professional practices and estimates of patient numbers (extrapolated from licensed data and inventory levels from key accounts, representative of our market).2

AE=adverse event; EOM=every other month; GA=geographic atrophy; ION=optic ischemic neuropathy; nAMD=neovascular age-related macular degeneration.

Back
GALE Efficacy
Next
Educational Media

References:  1. SYFOVRE (pegcetacoplan injection) [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2024. 2. Data on file. Apellis Pharmaceuticals, Inc.

Show more Show less

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion
    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).